A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer

BACKGROUND: Gastric cancer presents a major health burden worldwide. Therefore, many molecular targeting agents have been evaluated for treatment of gastric cancer. Gefitinib has shown anticancer activity against gastric cancer which work through inhibiting epidermal growth factor receptor (EGFR). H...

Descripción completa

Detalles Bibliográficos
Autores principales: Huafeng, Jia, Deqing, Zhang, Yong, Ding, Yulian, Zhang, Ailing, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879569/
https://www.ncbi.nlm.nih.gov/pubmed/29618949
http://dx.doi.org/10.1186/s12935-018-0548-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879569/
https://www.ncbi.nlm.nih.gov/pubmed/29618949
http://dx.doi.org/10.1186/s12935-018-0548-5

Ejemplares similares